ZVRA241115C9000
- 0.45
- +0.08+21.62%
Zevra Therapeutics Newsroom
Express News | Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign To Highlight Critical Importance Of Prompt, Accurate Blood Ammonia Testing For Diagnosing Urea Cycle Disorders
Guggenheim Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $20
Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $20
Zevra Therapeutics Analyst Ratings
Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Is Breakeven Near?
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $25
Investors in Zevra Therapeutics (NASDAQ:ZVRA) Have Seen Decent Returns of 67% Over the Past Year
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
JMP Securities analyst Jason Butler maintains $Zevra Therapeutics(ZVRA.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 39.2%
Zevra Started at Market Outperform by JMP on Miplyffa Approval
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
Zevra Therapeutics Price Target Announced at $17.00/Share by JMP Securities